ITM-11 significantly improved progression-free survival over everolimus in GEP-NETs patients, marking a first for targeted radiopharmaceutical therapy in a phase 3 trial. The COMPETE trial included ...
Median progression-free survival (PFS) in pancreatic neuroendocrine tumor (P-NET) patients was 24.5 months on 177Lu-edotreotide arm vs. 14.7 months on everolimus arm Objective response rate (ORR) was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results